AstraZeneca plc is an Anglo–Swedish multinational pharmaceutical and biopharmaceutical company.
In 2013, it moved its headquarters to Cambridge, United Kingdom, and concentrated its R&D in three sites: Cambridge, Gaithersburg, Maryland (location of MedImmune) for work on biopharmaceuticals, and Mölndal (near Gothenburg) in Sweden, for research on traditional chemical drugs. In 2015, it was the eighth-largest drug company in the world based on sales revenue.
AstraZeneca has a portfolio of products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation. The company was founded in 1999 through the merger of the Swedish Astra AB and the English Zeneca Group (itself formed by the demerger of the pharmaceutical operations of Imperial Chemical Industries in 1993). It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014).
news18 May 2022 | By Mandy Parrett (European Pharmaceutical Review)
The Phase III MANDALA trial has demonstrated that the combination medication PT027 significantly reduces the risk of severe exacerbation in patients with moderate to severe asthma, reports AstraZeneca.
news4 May 2022 | By Mandy Parrett (European Pharmaceutical Review)
AstraZeneca has announced plans to invest in a new facility, uniting its R&D activities with commercial and corporate functions in Boston, US.
news21 April 2022 | By European Pharmaceutical Review
Phase III trial shows Evusheld (tixagevimab and cilgavimab) significantly reduces the risk of developing symptomatic COVID-19 in vulnerable populations.
news8 April 2022 | By Hannah Balfour (European Pharmaceutical Review)
New Ultomiris (ravulizumab-cwvz) follow-up data shows sustained functional improvements in certain adults with generalised myasthenia gravis (gMG).
news22 March 2022 | By European Pharmaceutical Review
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has reported that Evusheld, developed by AstraZeneca, has been granted approval to help protect against the effects of COVID-19.
news18 March 2022 | By Hannah Balfour (European Pharmaceutical Review)
Lynparza® (olaparib) is the first PARP inhibitor to demonstrate overall survival benefit in early breast cancer, according to new data.
news3 March 2022 | By European Pharmaceutical Review
Nirsevimab has the potential to offer RSV protection for all infants, with a single dose showing 74.5 percent efficacy in the Melody Phase III trial.
news15 February 2022 | By European Pharmaceutical Review
A new collaborative initiative involving 15 large pharma companies will support diversity in executive roles and cross-company leadership skills development.
news21 January 2022 | By European Pharmaceutical Review
Patients treated with Imfinzi and chemotherapy experienced a 20 percent reduction in the risk of death versus chemotherapy alone.
news19 January 2022 | By Hannah Balfour (European Pharmaceutical Review)
Almost a third of unresectable hepatocellular carcinoma patients were alive at three years on tremelimumab and Imfinzi regimen.
news18 January 2022 | By Hannah Balfour (European Pharmaceutical Review)
US FDA grants Enhertu Priority Review based on promising trial results in certain patients with HER2-positive breast cancer.
news9 December 2021 | By Anna Begley (European Pharmaceutical Review)
The US Food and Drug Administration (FDA) issued an emergency use authorisation for AstraZeneca’s Evusheld for the pre-exposure prophylaxis of COVID-19.
news8 December 2021 | By Anna Begley (European Pharmaceutical Review)
AstraZeneca has entered into a new global development and commercialisation agreement with Ionis Pharmaceuticals for eplontersen.
news8 December 2021 | By Anna Begley (European Pharmaceutical Review)
Study finds six different COVID-19 vaccine boosters increase immunity and pose no safety concerns, although immune responses varied.
news1 December 2021 | By Anna Begley (European Pharmaceutical Review)
Over 600 people may benefit as NICE publishes final draft guidance recommending osimertinib within the Cancer Drugs Fund.